SCHEMBL333980

SCHEMBL333980

C1[N]CC2CNCC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14523284 0.75
SCHEMBL56397 0.75
SCHEMBL233307 0.75
SCHEMBL6991791 0.72 CHRNB2 (0.42)
Hydrochloric Acid SCHEMBL20534633 0.72
SCHEMBL14673280 0.72 CHRNB2 (0.42)
SCHEMBL27316 0.69
SCHEMBL166683 0.69
SCHEMBL15193376 0.69
SCHEMBL567378 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735270-B1 DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2010-06-30 EP claimed
US-7718675-B2 Diamino alcohols and their use as renin inhibitor SPEEDEL EXPERIMENTA AG (CH) 2010-05-18 US claimed
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US claimed
EP-2010180-A2 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2009-01-07 EP claimed
WO-2007124423-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-01 WO claimed
US-20070161622-A1 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis SPEEDEL EXPERIMENTA AG (CH) 2007-07-12 US claimed
US-4508723-A 6-Azaoligocycloalkylmethyleneaminopenam compounds CIBA GEIGY CORPORATION (US) 1985-04-02 US claimed
WO-2023247769-A1 DOSAGE REGIMEN FOR AXL INHIBITOR BERGENBIO ASA (NO) 2023-12-28 WO disclosed
US-20230372337-A1 Combination Therapy Comprising an AXL Inhibitor BERGENBIO ASA (NO) 2023-11-23 US disclosed
US-20230250169-A1 AXL Inhibitors for Antiviral Therapy BERGENBIO ASA (NO) 2023-08-10 US disclosed
US-20230149397-A1 Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus BERGENBIO ASA (NO) 2023-05-18 US disclosed
US-20230151100-A1 Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator BERGENBIO ASA (NO) 2023-05-18 US disclosed
EP-4138823-A1 METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR BerGenBio ASA (NO) 2023-03-01 EP disclosed
WO-2006135316-A1 New oxabispidine compounds for the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-12-21 WO disclosed
EP-1725530-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-11-29 EP disclosed
EP-1711456-A2 AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2006-10-18 EP disclosed
WO-2005090304-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-09-29 WO disclosed
WO-2005070870-A2 AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2005-08-04 WO disclosed
WO-2005070877-A1 DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2005-08-04 WO disclosed
US-4508723-A 6-Azaoligocycloalkylmethyleneaminopenam compounds CIBA GEIGY CORPORATION (US) 1985-04-02 US disclosed